A simple CD4+ T cells to FIB-4 ratio for evaluating prognosis of BCLC-B hepatocellular carcinoma: a retrospective cohort study

INTRODUCTION: Immunotherapy has become a new therapy for advanced hepatocellular carcinoma (HCC); however, its treatment results are considerably different. CD4+ T cells (CD4+) are the key to immunotherapy, but patients with HCC that have low CD4+ are rarely observed for clinical evidence. Hepatitis...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yong, Kong, Ling Xiang, Feng, Feng Shi, Yang, Jiayin, Wei, Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941753/
https://www.ncbi.nlm.nih.gov/pubmed/35321670
http://dx.doi.org/10.1186/s12885-022-09433-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941753/
https://www.ncbi.nlm.nih.gov/pubmed/35321670
http://dx.doi.org/10.1186/s12885-022-09433-3

Ejemplares similares